FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308406970> ?p ?o ?g. }

• W4308406970 abstract "<h3>Background</h3> Anti-programmed death 1/ligand 1 (PD-1/PD-L1) therapies have been established as standard treatment for multiple tumor types. However, the key challenge of these therapies is resistance caused by immunosuppressive factors in the tumor microenvironment (TME). TGF–β is a multi-functional cytokine that is involved in the tight regulation of either antitumor immunity or tumor immunosuppression. TGF–β promotes an immune exclusion TME thus renders PD-L1 blockade ineffective. Therefore, dual targeting PD-L1 and TGF–β represents a rational synergistic strategy to enhance clinical outcome relative to each agent alone. TST005 is a novel bi-functional fusion protein combining a high affinity PD-L1 monoclonal antibody (mAb) in a fragment crystallizable (Fc) silenced immunoglobulin G1 (IgG1) backbone and a differentiated transforming growth factor beta (TGF–β) trap with improved stability. This study will investigate TST005’s safety, tolerability and preliminary anti-tumor activity in solid tumors. <h3>Methods</h3> This Phase 1, first in human (FIH) study is an open-label, multicenter trial that consists of a dose escalation phase in patients with advanced solid tumors who has failed prior therapy followed by a dose expansion phase in human papillomavirus (HPV) related malignancies that is not amenable to surgeryand have received prior standard therapy(ies). The primary objectives are to evaluate the safety and tolerability and determine the maximum tolerated dose or recommended Phase 2 dose(s) of TST005. Secondary objectives include pharmacokinetic, pharmacodynamic and preliminary anti–tumor activity of TST005. The dose escalation phase comprises five dose cohorts: accelerated titration of 1 subject in the starting dose cohort (1 mg/kg), and then four dose cohorts (3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg) following classic 3+3 design. No more than one prior immune checkpoint inhibitor (ICI) treatment is allowed for eligible subjects. In the dose expansion phase, up to 30 patients with locally advanced or metastatic HPV+ malignancies, including cervical cancers, P16+ Oropharyngeal cancers, and other tumors that are known HPV+, and who are ICI treatment naive will be enrolled. Subjects will receive TST005 intravenous infusion every 3 weeks (Q3W) until disease progression per RECIST v1.1 and/or immune RECIST or unacceptable toxicity. Subjects may continue to receive TST005 beyond RECIST v1.1 defined progression at the discretion of the Investigator. This study is ongoing at 4 sites in the US and China. As of the 30 June, 2022, the first two dose cohorts evaluation has been completed and no DLT was observed. Clinical trial information: NCT04958434. Study Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. <h3>Ethics Approval</h3> The study obtained sites’ IRB approval for as listed below. All participants gave informed consent before taking part. - Salus IRB (NXSAT20.69) - Advarra IRB (SSU00157936) - Mary Crowley Medical Research Center IRB (21-37) - Shanghai Cancer Center IRB (2112248-1-2203) <h3>Consent</h3> Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal." @default.
• W4308406970 created "2022-11-11" @default.
• W4308406970 creator A5010738468 @default.
• W4308406970 creator A5015591858 @default.
• W4308406970 creator A5029042444 @default.
• W4308406970 creator A5030029091 @default.
• W4308406970 creator A5035336399 @default.
• W4308406970 creator A5051338860 @default.
• W4308406970 creator A5052713292 @default.
• W4308406970 creator A5057209439 @default.
• W4308406970 creator A5060992997 @default.
• W4308406970 creator A5066277505 @default.
• W4308406970 creator A5082283453 @default.
• W4308406970 creator A5082586117 @default.
• W4308406970 date "2022-11-01" @default.
• W4308406970 modified "2023-10-15" @default.
• W4308406970 title "771 A phase 1, first in human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumors" @default.
• W4308406970 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0771" @default.
• W4308406970 hasPublicationYear "2022" @default.
• W4308406970 type Work @default.
• W4308406970 citedByCount "0" @default.
• W4308406970 crossrefType "proceedings-article" @default.
• W4308406970 hasAuthorship W4308406970A5010738468 @default.
• W4308406970 hasAuthorship W4308406970A5015591858 @default.
• W4308406970 hasAuthorship W4308406970A5029042444 @default.
• W4308406970 hasAuthorship W4308406970A5030029091 @default.
• W4308406970 hasAuthorship W4308406970A5035336399 @default.
• W4308406970 hasAuthorship W4308406970A5051338860 @default.
• W4308406970 hasAuthorship W4308406970A5052713292 @default.
• W4308406970 hasAuthorship W4308406970A5057209439 @default.
• W4308406970 hasAuthorship W4308406970A5060992997 @default.
• W4308406970 hasAuthorship W4308406970A5066277505 @default.
• W4308406970 hasAuthorship W4308406970A5082283453 @default.
• W4308406970 hasAuthorship W4308406970A5082586117 @default.
• W4308406970 hasBestOaLocation W43084069701 @default.
• W4308406970 hasConcept C111113717 @default.
• W4308406970 hasConcept C112705442 @default.
• W4308406970 hasConcept C126322002 @default.
• W4308406970 hasConcept C143998085 @default.
• W4308406970 hasConcept C159654299 @default.
• W4308406970 hasConcept C197934379 @default.
• W4308406970 hasConcept C203014093 @default.
• W4308406970 hasConcept C2776107976 @default.
• W4308406970 hasConcept C2776146153 @default.
• W4308406970 hasConcept C2777701055 @default.
• W4308406970 hasConcept C2778375690 @default.
• W4308406970 hasConcept C2780252810 @default.
• W4308406970 hasConcept C2780850621 @default.
• W4308406970 hasConcept C3875195 @default.
• W4308406970 hasConcept C502942594 @default.
• W4308406970 hasConcept C542903549 @default.
• W4308406970 hasConcept C71924100 @default.
• W4308406970 hasConcept C8891405 @default.
• W4308406970 hasConcept C98274493 @default.
• W4308406970 hasConceptScore W4308406970C111113717 @default.
• W4308406970 hasConceptScore W4308406970C112705442 @default.
• W4308406970 hasConceptScore W4308406970C126322002 @default.
• W4308406970 hasConceptScore W4308406970C143998085 @default.
• W4308406970 hasConceptScore W4308406970C159654299 @default.
• W4308406970 hasConceptScore W4308406970C197934379 @default.
• W4308406970 hasConceptScore W4308406970C203014093 @default.
• W4308406970 hasConceptScore W4308406970C2776107976 @default.
• W4308406970 hasConceptScore W4308406970C2776146153 @default.
• W4308406970 hasConceptScore W4308406970C2777701055 @default.
• W4308406970 hasConceptScore W4308406970C2778375690 @default.
• W4308406970 hasConceptScore W4308406970C2780252810 @default.
• W4308406970 hasConceptScore W4308406970C2780850621 @default.
• W4308406970 hasConceptScore W4308406970C3875195 @default.
• W4308406970 hasConceptScore W4308406970C502942594 @default.
• W4308406970 hasConceptScore W4308406970C542903549 @default.
• W4308406970 hasConceptScore W4308406970C71924100 @default.
• W4308406970 hasConceptScore W4308406970C8891405 @default.
• W4308406970 hasConceptScore W4308406970C98274493 @default.
• W4308406970 hasLocation W43084069701 @default.
• W4308406970 hasOpenAccess W4308406970 @default.
• W4308406970 hasPrimaryLocation W43084069701 @default.
• W4308406970 hasRelatedWork W1934667138 @default.
• W4308406970 hasRelatedWork W2028648326 @default.
• W4308406970 hasRelatedWork W2090169689 @default.
• W4308406970 hasRelatedWork W2112620969 @default.
• W4308406970 hasRelatedWork W2122556001 @default.
• W4308406970 hasRelatedWork W2626992247 @default.
• W4308406970 hasRelatedWork W2922882148 @default.
• W4308406970 hasRelatedWork W2977681113 @default.
• W4308406970 hasRelatedWork W3120853613 @default.
• W4308406970 hasRelatedWork W4319063555 @default.
• W4308406970 isParatext "false" @default.
• W4308406970 isRetracted "false" @default.
• W4308406970 workType "article" @default.